The U.S. Food and Drug Administration has granted approval to Amgen for their biosimilar version of Johnson & Johnson's popular psoriasis treatment, Stelara, for the treatment of various inflammatory diseases.
- The U.S. Food and Drug Administration on Tuesday approved Amgen 's biosimilar version of Johnson & Johnson 's blockbuster psoriasis treatment Stelara for multiple inflammatory diseases.
FDA Amgen Biosimilar Stelara Johnson & Johnson Psoriasis Inflammatory Diseases
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen Beats Earnings Expectations and Expands into Obesity Drug SpaceAmgen reported better-than-expected third-quarter earnings and raised its revenue guidance for the full year. The company recently acquired Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also venturing into the obesity drug market and has completed enrollment for a phase 2 trial for the treatment of obesity.
Read more »
Amgen third-quarter sales rise 5%; profit up before chargeAmgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit...
Read more »
Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
Read more »
FDA says WanaBana fruit puree pouches may contain dangerous levels of leadThe U.S. Food and Drug Administration is warning parents and caregivers not to buy or serve certain pureed fruit pouches marketed to toddlers and young...
Read more »